Educational research on US and Indian equities, ETFs, mutual funds and crypto, with screeners and a free investing academy.
All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 5 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $7M | $-221M | $-212M | $-207M | -33.5% | -23.2% | -27.5% |
| 2024 | $9M | $-151M | $-293M | $-164M | -161.7% | -35.5% | 174.3% |
| 2023 | $14M | $-28M | $-107M | $-8M | -89.1% | - | 189.5% |
| 2022 | $0M | $-36M | $-37M | $-29M | -221.6% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2025 |
|---|---|
| Total Revenue | 6.94 |
| Operating Revenue | 6.94 |
| Operating Expense | 231.05 |
| Research And Development | 187.29 |
| Selling General And Administration | 43.77 |
| Total Expenses | 231.05 |
| Operating Income | -224.11 |
| Total Operating Income As Reported | -224.11 |
| EBITDA | -221.16 |
| Normalized EBITDA | -221.16 |
| EBIT | -224.11 |
| Interest Income | 11.72 |
| Interest Expense | - |
| Net Interest Income | 11.72 |
| Other Non Operating Income Expenses | - |
| Other Income Expense | - |
| Interest Income Non Operating | 11.72 |
| Interest Expense Non Operating | - |
| Net Non Operating Interest Income Expense | 11.72 |
| Pretax Income | -212.39 |
| Tax Rate For Calcs | 0 |
| Tax Effect Of Unusual Items | 0 |
| Net Income Continuous Operations | -212.39 |
| Net Income From Continuing And Discontinued Operation | -212.39 |
| Net Income From Continuing Operation Net Minority Interest | -212.39 |
| Net Income | -212.39 |
| Net Income Common Stockholders | -212.39 |
| Net Income Including Noncontrolling Interests | -212.39 |
| Normalized Income | -212.39 |
| Diluted NI Availto Com Stockholders | -212.39 |
| Basic Average Shares | 87.35 |
| Diluted Average Shares | 87.35 |
| Reconciled Depreciation | 2.96 |
| Total Unusual Items | - |
| Total Unusual Items Excluding Goodwill | - |
| Special Income Charges | - |
| Other Special Charges | - |
| Restructuring And Mergern Acquisition | - |
| General And Administrative Expense | 43.77 |
| Other Gand A | 43.77 |
| Total Other Finance Cost | - |
| Otherunder Preferred Stock Dividend | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Immunome, Inc.this co. | IMNM | $2.2B | -10.49 | 3.51 | -33.5% | -7.14 |
| Celldex Therapeutics, Inc. | CLDX | $2.3B | -9.08 | 4.46 | -49.1% | -8.18 |
| Axogen, Inc. | AXGN | $2.3B | - | 17.49 | -12.2% | 4471.19 |
| Mineralys Therapeutics, Inc. | MLYS | $2.2B | -14.28 | 3.41 | -23.9% | - |
| Enliven Therapeutics, Inc. | ELVN | $2.2B | -20.85 |
| - |
| - |
| - |
| - |
| 4.70 |
| -22.6% |
| -17.28 |
| BioCryst Pharmaceuticals, Inc. | BCRX | $2.2B | 8.16 | -18.07 | -221.4% | 7.20 |
| Kodiak Sciences Inc. | KOD | $2.1B | - | 13.58 | -146.1% | - |
| Aurinia Pharmaceuticals Inc. | AUPH | $2.1B | 7.33 | 3.62 | 49.4% | 15.22 |
| Clover Health Investments, Corp. | CLOV | $2.1B | -24.56 | 6.81 | -27.7% | - |
| Peer Median | - | -11.68 | 4.58 | -25.8% | 7.20 | |